Matter P, Burch H B
Surgical Department, Hospital of Davos, Switzerland.
Arch Orthop Trauma Surg. 1990;109(6):311-3. doi: 10.1007/BF00636167.
AO/ASIF with its collaborating laboratories has developed cold worked pure titanium material for implants with an outstanding biocompatibility. The first prospectively controlled clinical series dates back to 1966 and was reported to be most successful. Pure titanium also became the material of choice for implants to be used in patients suffering from metal allergy. Today, a long-term and well-documented experience with these implants exists. It therefore seemed logical to use pure titanium for the new limited contact dynamic compression plate (LC-DCP) system described in the previous article by Perren. Pilot clinics started to implant titanium LC-DCP in 1987, and already 271 plates have been used, mainly for the treatment of fresh fractures. Some 57 plates have so far been removed. The preliminary results are most favourable; they confirm especially the outstanding biocompatibility of pure titanium.
AO/ASIF及其合作实验室开发了用于植入物的冷加工纯钛材料,其具有出色的生物相容性。第一个前瞻性对照临床系列可追溯到1966年,据报道非常成功。纯钛也成为患有金属过敏患者植入物的首选材料。如今,对于这些植入物已有长期且记录完备的经验。因此,使用纯钛制造前文佩伦所描述的新型有限接触动力加压钢板(LC-DCP)系统似乎是合理的。试点诊所于1987年开始植入钛制LC-DCP,至今已使用了271块钢板,主要用于治疗新鲜骨折。到目前为止,已取出约57块钢板。初步结果非常令人满意;它们特别证实了纯钛出色的生物相容性。